Our wildest dream have come true i couldnt imagine $17.00 closing price for 2013.
I know God willing our dreams will be even closer to reality in 2014 .
Many thanks to Mr; Lewis for his superior leadership and as we all know he is the reason for all of Insmed's success so far and may he be successful to the end for the sake of the patients.
Best regards to all true longs of Insmed.
I want to wish everyone on this board a happy, healthy and wealthy new year.
Certainly when the share price hit $14.30 in May - and analysts were valuing the stock at anywhere from $18 to $24 with Phase III success - I personally never dreamed for one moment that Arikace would succeed at Phase III and we'd be sitting at $17 six months later courtesy of a second toxic dilution in the mere nine months Lewis has been in charge.
There is indeed much that we can thank Lewis for - and I suspect we can eagerly look forward to more of his unique take on delivering shareholder value when news from the NTM study arrives this quarter.